Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection

Gastroenterology

Volumn 123, Issue 6, 2002, Pages 1831-1838

  Lai, Ching Lung ^a   Rosmawati, Mohamed ^b   Lao, Judy ^c   Van Vlierberghe, Hans ^d   Anderson, Frank H ^e   Thomas, Neal ^f   Dehertogh, Deborah ^f  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

^c Cebu Doctors Hospital   (Philippines)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEROCONVERSION; VERTIGO; VIRUS INHIBITION; VIRUS LOAD;

EID: 0036892435     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.37058     Document Type: Article

References (26)

1. de Man R, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, Lee Y, Mazzotta F, Thema N, DeHertagh D. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582.
2. WHO/OMS. Hepatitis B. Fact Sheet. Infectious Diseases 2000.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
4. Wong DK, Cheung AM, O'Rourke K, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
5. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters K-A, Tyrrell DL, Brown N, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
6. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
7. Niesters HG, Honkoop P, Haagsma EB, deMan RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-1385.
8. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antiviral Chem Chemother 2001;12(suppl 1);67-71.
9. Seifer M, Hamatake RK, Colonno RJ, Standring D. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-3208.
10. Bristol-Myers Squibb. Data on file. Wallingford, CT: Bristol-Myers Squibb.
11. Yamanaka G, Wilson T, Innaimo S, Bisacch G, Egli P, Rinehart JK, Zahler R, Colonno R. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-193.
12. Marion PL, Salazar FH, Winters MA, Colonno R. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-88.
13. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham S, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant B, Rose B, Clark J. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-1245.
14. Zeuzem S, De Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-436.
15. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
16. Whalley SA, Murray JM, Brown D, Webster GJ, Emery VC, Dusheiko GH, Perelson AS. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193:847-854.
17. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
18. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
19. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-1026.
20. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
21. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
22. Balfour HHJ. Antiviral drugs. N Engl J Med 1999;340:1255-1268.
23. Hayden FG. Antimicrobial agents (continued) antiviral agents (Nonretroviral). In: Hardman JG, Limbird LE, eds. Goodman and Gilman's: The Pharmacologic Basis of Therapeutics. 10th Ed. New York: McGraw-Hill, 2001:1313-1347.
24. Honkoop P, De Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
25. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
26. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Rutkiewicz V, Thomas N, Denisky G, Joshi S. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy (abstr). Hepatology 2001;34:340A.